Physician profile
Michael Stany
NPI 1740266832
$12,560.74
in general payments reported to CMS, 2019-2025
17 companies · $849 in 2025
The $849 reported for 2025 was more than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,240 · 2020: $106 · 2021: $244 · 2022: $1,987 · 2023: $3,013 · 2024: $121 · 2025: $849.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,740 · Food and Beverage: $1,244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,740.00 |
| Food and Beverage | $1,243.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tesaro, INC. | $5,862.20 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $2,799.29 | 2023-2025 | Lynparza |
| Intuitive Surgical, INC. | $2,636.99 | 2019-2023 | Da Vinci Surgical System |
| Glaxosmithkline, LLC. | $356.04 | 2020-2025 | Jemperli, Zejula |
| Merck Sharp & Dohme LLC | $258.27 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Seagen INC. | $122.67 | 2021 | |
| Stemline Therapeutics INC. | $119.16 | 2025 | Orserdu |
| Daiichi Sankyo INC. | $77.90 | 2025 | Enhertu, Datroway |
| Clovis Oncology, INC. | $66.79 | 2019-2021 | |
| Eisai INC. | $59.43 | 2025 | |
| Abbvie INC. | $50.19 | 2025 | |
| Corcept Therapeutics | $49.52 | 2025 | Korlym |
| Verastem, INC. | $31.06 | 2025 | Avmapki Fakzynja Co-Pack |
| Pfizer INC. | $23.11 | 2025 | |
| Accord Healthcare, INC. | $16.56 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lsi Solutions INC | $16.09 | 2025 | Fornisee |
| Fennec Pharmaceuticals, INC. | $15.47 | 2025 | Fyarro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Stany listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.